The discoveries that BRUCE/PTEN dual deficiency converges on STAT3 hyperactivation and that inhibition of STAT3 ameliorates MASLD/MASH pathogenesis represent mechanistic, clinical, and therapeutic breakthroughs in MASLD/MASH research. This evidence concerns the gene PTEN and metabolic dysfunction-associated steatohepatitis.